Zhana K. Karneva
Research Subjects
Research Interests
Zhana K. Karneva has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Angela Helfricht
ProQR Therapeutics NV, Leiden, Netherlands
1 shared publication Frits van der Ham
ProQR Therapeutics NV, Leiden, Netherlands
1 shared publication- Frédéric Saudou
Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neuroscience
1 shared publication Geert B. van der Horst
ProQR Therapeutics NV, Leiden, Netherlands
1 shared publication- Gerard J. Platenburg
ProQR Therapeutics NV, Leiden, Netherlands
1 shared publication - Hans Hebert
KTH Royal Inst Technol, Sch Engn Sci Chem Biotechnol & Hlth, Dept Biomed Engn & Hlth Syst, S-14152 Huddinge, Sweden
1 shared publication
Latest Publications
- Open Access
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
A pathogenic proteolysis–resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function
Huntington’s disease (HD) is a late-onset neurological disorder for which therapeutics are not available. Its key pathological mechanism involves the proteolysis of polyglutamine-expanded (polyQ-expanded) mutant huntingtin (mHTT), which generates N-terminal fragments containing polyQ, a key contributor to HD pathogenesis. Interestingly, a naturally occurring spliced form of HTT mRNA with truncated exon 12 encodes an HTT (HTT Δ12 ) with a deletion near the caspase-6 cleavage site. In this study, we used a multidisciplinary approach to characterize the therapeutic potential of targeting HTT exon 12. We show that HTT Δ12 was resistant to caspase-6 cleavage in both cell-free and tissue lysate assays. However, HTT Δ12 retained overall biochemical and structural properties similar to those of wt-HTT. We generated mice in which HTT exon 12 was truncated and found that the canonical exon 12 was dispensable for the main physiological functions of HTT, including embryonic development and intracellular trafficking. Finally, we pharmacologically induced HTT Δ12 using the antisense oligonucleotide (ASO) QRX-704. QRX-704 showed predictable pharmacology and efficient biodistribution. In addition, it was stable for several months and inhibited pathogenic proteolysis. Furthermore, QRX-704 treatments resulted in a reduction of HTT aggregation and an increase in dendritic spine count. Thus, ASO-induced HTT exon 12 splice switching from HTT may provide an alternative therapeutic strategy for HD.
- 8 September 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (17)
Open AccessA pathogenic proteolysis–resistant huntingtin isoform induced by an antisense oligonucleotide maintains huntingtin function
Huntington’s disease (HD) is a late-onset neurological disorder for which therapeutics are not available. Its key pathological mechanism involves the proteolysis of polyglutamine-expanded (polyQ-expanded) mutant huntingtin (mHTT), which generates N-terminal fragments containing polyQ, a key contributor to HD pathogenesis. Interestingly, a naturally occurring spliced form of HTT mRNA with truncated exon 12 encodes an HTT (HTT Δ12 ) with a deletion near the caspase-6 cleavage site. In this study, we used a multidisciplinary approach to characterize the therapeutic potential of targeting HTT exon 12. We show that HTT Δ12 was resistant to caspase-6 cleavage in both cell-free and tissue lysate assays. However, HTT Δ12 retained overall biochemical and structural properties similar to those of wt-HTT. We generated mice in which HTT exon 12 was truncated and found that the canonical exon 12 was dispensable for the main physiological functions of HTT, including embryonic development and intracellular trafficking. Finally, we pharmacologically induced HTT Δ12 using the antisense oligonucleotide (ASO) QRX-704. QRX-704 showed predictable pharmacology and efficient biodistribution. In addition, it was stable for several months and inhibited pathogenic proteolysis. Furthermore, QRX-704 treatments resulted in a reduction of HTT aggregation and an increase in dendritic spine count. Thus, ASO-induced HTT exon 12 splice switching from HTT may provide an alternative therapeutic strategy for HD.